BWX Technologies, Inc. (NYSE:BWXT) has announced robust first-quarter results for 2024, with significant organic revenue growth and plans for expansion to meet increasing demand in the commercial nuclear sector. The company reported a 6% increase in organic revenue and a 9% rise in adjusted earnings per share.
Additionally, BWX Technologies is undertaking a substantial expansion of its Cambridge plant, bolstering its position as North America's premier heavy nuclear equipment manufacturer. The expansion is expected to enhance the plant's capacity by 25% and incorporate advanced manufacturing technology, with an investment of $60 million over two years.
Key Takeaways
- BWX Technologies experienced a 6% organic revenue growth and a 9% increase in adjusted earnings per share in Q1 2024.
- The company announced a 25% expansion of its Cambridge plant, with a $60 million investment over the next two years.
- BWXT's Pickering site units 5 through 8 are set to drive backlog and revenue growth for the next decade.
- BWXT Medical is witnessing rapid revenue growth, with plans to ramp up commercial sales of lutetium next year.
- The company reaffirmed its full-year guidance for mid-single-digit revenue and adjusted EBITDA growth.
- Revenue for Q1 stood at $604 million, with adjusted EBITDA at $115 million, marking a 4% year-over-year increase.
- Full-year revenue is projected to be at least $2.6 billion, with adjusted EBITDA around $500 million.
- Capital expenditures for the year are expected to align with previous plans, ranging from $100-130 million.
Company Outlook
- BWX Technologies reaffirms its 2024 guidance, focusing on capturing growth opportunities and achieving medium-term financial targets.
- The company expects robust demand in commercial nuclear markets to continue driving growth.
- BWXT is working closely with GE Hitachi (OTC:HTHIY) on the BWRX 300 project and anticipates a full manufacturing award soon.
Bearish Highlights
- Some new projects and advanced technology group initiatives have lower margins, affecting profitability.
- Labor challenges have put pressure on margins and increased overhead costs.
Bullish Highlights
- BWXT is the sole commercial supplier of non-carrier-added actinium, positioning it well in the market.
- The company is confident in its ability to meet the Navy's demands despite labor challenges.
Misses
- The multi-year pricing negotiation was delayed due to funding uncertainty but is now close to finalization.
- The approval for TC99 in the medical business is expected to face delays.
Q&A Highlights
- CEO Rex Geveden addressed concerns about slowed submarine production, emphasizing the company's decoupling from shipyard schedules.
- BWXT has successfully reengineered its talent acquisition process, hiring 10% of its workforce last year to meet growth needs.
In conclusion, BWX Technologies maintains a strong market position with promising expansion plans and a steady focus on its long-term financial goals. The company's initiatives in the commercial nuclear and medical sectors are poised to bolster its revenue and backlog, despite facing some challenges in labor and project margins. BWXT's strategic moves, including plant expansions and partnerships, are expected to contribute positively to its future performance.
InvestingPro Insights
As BWX Technologies (BWXT) continues to chart a strong course in the commercial nuclear sector, key financial metrics and InvestingPro Tips provide a deeper look into the company's performance and market position. With a market capitalization of $9.04 billion and a revenue growth of 11.8% over the last twelve months as of Q1 2023, BWXT showcases a significant presence in its industry.
InvestingPro Tips highlight that BWXT has raised its dividend for 8 consecutive years, underlining a commitment to shareholder returns. Additionally, the company has maintained dividend payments for 13 consecutive years, which may reassure investors looking for consistent income streams. These dividends are supported by the fact that BWXT's liquid assets exceed short-term obligations, indicating a solid financial footing that could sustain future dividend payments.
From a valuation perspective, BWXT is trading at a high earnings multiple, with a P/E ratio of 36.73 and a high Price / Book multiple of 9.68 as of the last twelve months ending Q4 2023. This suggests that investors are willing to pay a premium for BWXT's shares, potentially due to the company's strong market position and future growth prospects.
Investors interested in BWXT's financial health and future outlook can find additional InvestingPro Tips at https://www.investing.com/pro/BWXT. There are currently 17 additional tips available, providing a comprehensive understanding of the company's performance and potential. For those looking to delve deeper into BWXT's investment profile, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
Full transcript - Babcock & Wilcox (BWXT) Q1 2024:
Operator: Ladies and gentlemen, welcome to the BWX Technologies First Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. Following the company's prepared remarks, we will conduct a question-and-answer session. And instruction will be given at the time. I would like to turn the call over to our host, Chase Jacobson of BWXT's Vice President of Investor Relations. Please go ahead.
Chase Jacobson: Thank you, Kathleen. Good evening and welcome to today's call. Joining me are Rex Geveden, President and CEO, and Robb LeMasters, Senior Vice President and CFO. On today's call, we will reference the first quarter 2024 earnings presentation that is available on the investor section of the BWXT website. We will also discuss certain matters that constitute forward-looking statements. These statements involve risks and uncertainties including those described in the Safe Harbor provision found in the investor materials in the company's SEC filings. We will frequently discuss non-GAAP financial measures which are reconciled to GAAP measures in the appendix of the earnings presentation that can be found on the investor section of the BWXT website. I would now like to turn the call over to Rex.
Rex Geveden: Thank you, Chase, and good evening to all of you. This afternoon, we reported the BWXT first quarter results. We delivered 6% organic revenue growth, 9% adjusted earnings per share growth, and remarkably good cash flow compared to historical seasonal patterns. Operating performance was in line with our expectations, and we are reaffirming our full-year guidance, calling for mid-single-digit revenue and adjusted EBITDA growth, leading to adjusted earnings per share of $3.05 to $3.20. Before I get into the segment discussion, I'd like to spend a few minutes on our recent announcement to expand the Cambridge plant, which is already North America's largest heavy nuclear equipment manufacturing facility. As we discussed on recent calls, demand in the commercial nuclear markets is robust with new and ongoing life extensions of CANDU reactors in Canada and the international market, the potential for large new builds, and the incipient demand for small modular reactors. With this tangible future demand and our existing commercial nuclear backlog of over $700 million, we are moving forward with a project to increase the Cambridge facility footprint by 25% and upgrade it with advanced manufacturing equipment. Over the next two years, we will invest about $60 million with construction starting in the third quarter of this year and planned completion in mid-2026. I would add that the expanded capacity enables more efficient execution of our existing backlog and room for new and exciting growth projects. While much smaller in scale, our intention is to get ahead of demand that we know is precipitating in this market, just as we did with naval propulsion, microreactors, and the medical business in recent years. This investment also enables our customers to signal supply chain strength as they compete for and secure more clean energy projects. In that vein, just last week, GE Vernova announced that BWXT is the first qualified company in the BWRX 300 supply chain group. Our customers require products that meet extremely high-quality standards with on-time delivery. By making meaningful investments now, we will be ready to satisfy the demand at the right time with market-leading credentials and capacity. Before making this investment, I'm personally engaged in discussions with our top customers and will be on the road visiting with others over the next couple of months to underscore BWXT's commitment to the industry and our need to generate appropriate returns for the value we provide. As capacity inevitably tightens, BWXT will occupy an enviable position given its world-class workforce, facilities, and experiential qualifications. Now turning to a discussion of segment results and the market outlook, government operations continue to grow nicely with 6% organic revenue growth in the quarter. From a demand perspective, I would like to touch on a couple of key areas. First, at a high level, the long-delayed fiscal 2024 appropriations provided good funding across all our programs and government operations. Looking beyond this year, the President's fiscal year '25 budget supports the secular themes, namely the great power competition and global decarbonization that underpin BWXT's long-term growth story. The request prioritizes the Columbia-class submarine program and provides substantial investment in modernization of the submarine industrial base to sustain the shipbuilding plan and prepare for AUKUS. This was further supported with $3.3 billion of the defense supplemental bill that was just signed by the President. The FY'25 request supports clean energy, including investments in advanced nuclear technology development, which is important for growth in the micro and small modular reactor markets. More specifically, it fully funds NASA and DARPA's DRACO project, the first demonstration of a nuclear thermal rocket engine in space, a program in which BWXT is manufacturing the reactor hardware and complex coated fuel. Second, there's been a lot of recent news flow around delays in Navy shipbuilding at U.S. shipyards and changes in the procurement schedules reflected in the Navy's new 30-year shipbuilding plan. To address the shipbuilding delays, I will remind you that BWXT made early, significant investments to ensure we could handle the workload associated with the serial ramp and Columbia-class orders concurrent with two Virginia-class orders per year and carrier work going through our facilities. For the most part, we have successfully navigated some of the labor and supply chain issues at the shipyards during and post-COVID. Accordingly, we are somewhat decoupled from the shipbuilding delays. That said, we remain vigilant and continue to work with our customers to ensure the stability of our execution schedules. The updated 30-year shipbuilding plan, released since we last spoke at Investor Day just over two months ago, reflects pressures and trade-offs the Navy sees amid tighter times with varied priorities. While plans for the Virginia-class are mixed, that is not particularly meaningful to BWXT given our backlog of work, but the Navy's potential adjustment to the Ford-class aircraft carrier schedule would be more impactful because of the reactor scale and quantities. According to this new plan, CVN-82 will be procured in 2030 rather than in 2028, with advanced procurement starting in 2027 rather than 2026. For BWXT, this could mean that the carrier lull in '24 and '25 could be extended another year. As we are doing in 2024, we will aim to offset this potentially extended lull with other programs. In any case, our visibility into the demand for naval propulsion reactors, components, and fuel work remains clear with steady procurement cadence of Virginia-class submarines and serial production of Columbia-class submarines. Additionally, while still early, it is possible that the Navy could use an extended carrier lull to get ahead on AUKUS-related work. BWXT has received funding for initial architectural and engineering facilitation work scopes to support future increased workload demand, including potential AUKUS activity. While the cadence of orders on any specific ship set could shift from year-to-year, we believe the 10-year compound growth rate for our naval propulsion business of 3% to 5% that we laid out in Investor Day remains achievable. The nation is doubtlessly committed to its long-term goals for the nuclear fleet, and changes under various administrations or other Washington dynamics have not historically supplanted the national security imperative. Our microreactor projects for both land and sea are progressing nicely. Project Pele, the terrestrial microreactor we are developing with the Strategic Capabilities Office, is in the procurement phase, and we are working alongside Idaho National Lab and the DOE to finalize the requirements for the authorization basis needed for licensing operation of the system. It is worth noting that Pele received the full funding request in the fiscal 2024 defense bill, highlighting the government support for this critical technology, one that could ultimately serve as a strategic advantage due to increasing needs for stable power at remote military bases and for applications including high-powered radars and the electrification of military tactical vehicles and weapons. Similarly, while in its early stages, DRACO was ramping nicely and was a key contributor to revenue growth in the quarter. Beyond DRACO, we continue to build on our space franchise as the U.S. and its allies increasingly invest in nuclear technologies to expand their presence and capabilities in this domain. We recently entered a teaming agreement with Rolls-Royce (OTC:RYCEY) through which we secured a U.K. space agency contract for nuclear space power missions. This teaming agreement provides for expanding our collaboration beyond space and into other advanced nuclear applications, including microreactor and small modular reactor fuel and component development. While our microreactor strategy is primarily focused on defense applications, we continue to assess opportunities in the commercial markets. Our history of manufacturing nuclear reactors for the Navy, along with our dedicated manufacturing footprint and significant technical expertise position as well as commercial opportunities materialize. In special materials, we've assembled a deep portfolio based on our strengths and technical capabilities in radiochemical processing, handling, and accountability. Earlier this year, we announced a two-year extension of our downblending contract, building on the success of 2023 when we captured a five-year uranium purification and conversion contract and a multi-year contract to recycle scrap material from the Y-12 National Security Complex into high-SA, low-enriched uranium. In March, a BWXT-led joint venture was awarded the 10-year Hanford Integrated Tank Disposition Contract by the DOE. We were first awarded this contract in April 2023. After multiple protests by the incumbent, the DOE decided to re-award the contract to the BWXT-led joint venture. While it is again being protested, we delivered a superior proposal as evidenced by our being selected twice. Assuming it settles in our favor, we expect a contract transition later this year. While we are encouraged by market demand, we also remain keenly focused on improving our operations. As I discussed before, we've made significant investments in our workforce and facilities. In the first quarter, we continued to realize benefits of our operational equipment effectiveness program as we saw improved efficiency metrics across our key sites. By way of example, the team tasked with improving tube sheet drilling, a process that requires immense precision, nearly doubled the efficiency of this work track. This is just one example of how our focus on OpEx is helping to drive profitability and offset inflationary impacts to the business. Turning now to our commercial operations segment. Revenue in the segment grew 7% in the quarter and adjusted EBITDA was up 55%. Continuing a recent trend, growth was driven by increasing demand for medical isotopes and improved medical EBITDA contribution. As I described earlier in the call, demand in the commercial nuclear power market is strong. At the end of January, Ontario Power Generation formally announced that it will proceed with life extension of the Pickering site units 5 through 8. This is a substantial opportunity for BWXT that will drive backlog and revenue growth and provide another 10 years or more of visibility into our backlog of life extension work that began in that region in 2017. In the SMR market, we are working with GE Hitachi on the reactor pressure vessel for the BWRX 300 project with OPG and anticipate a full release of the manufacturing award in the coming months. And our opportunity set remains enticing as utilities in North America and Europe consider building SMRs to meet growing electricity demand. The expansion at Cambridge that I described earlier improves our position as the preeminent supplier of large nuclear equipment in North America. Turning to BWXT Medical, revenue grew rapidly building on the momentum from last year with base diagnostics and contract drug manufacturing expansion. We continue to expect full-year medical revenue growth of about 25%. Demand for diagnostic and therapeutic isotopes is increasing and rapid consolidation of the therapeutic space continued with AstraZeneca (NASDAQ:AZN)'s announcement to acquire Fusion Pharmaceuticals, a key partner of BWXT and a leader in actinium-based drug development for up to $2.4 billion. We continue to see positive data points as various actinium and lutetium-based radiopharmaceuticals advance through clinical trials driving significant growth in the addressable market. There are over 155 active clinical trials for drugs using these isotopes, some involving drugs that have already proven to be successful. For example, Novartis (SIX:NOVN) recently announced that it will seek approval for Pluvicto use in the pre-chemotherapy setting. Pluvicto is the market-leading lutetium-based prostate cancer drug with over a billion in annual sales and is currently only approved for post-chemotherapy settings. Approval would open a significantly larger patient set, highlighting the meaningful growth potential of this market. We are currently the only commercial supplier of non-carrier-added actinium and are supporting multiple clinical trials and plan to ramp commercial sales of lutetium significantly next year as we finalize our drug master file with the FDA. So overall, we had a good quarter and are reaffirming our 2024 guidance. BWXT is at the forefront of the nuclear industry, occupying meaningful competitive positions in multiple markets. We are experiencing secular tailwinds over the long-term in a portfolio that can withstand near-term demand and funding variability. We have a highly credentialed experience workforce, unique infrastructure, and world-class capabilities in manufacturing, processing, and services, and are enhancing these with organic investments. We are committed to providing our customers nuclear solutions to address critical missions in global security, clean energy, interventional oncology, and other nuclear applications, positioning us well to achieve our medium-term financial targets. With that, I will now turn the call over to Robb.
Robb LeMasters: Thanks, Rex, and good evening, everyone. I'll start with some total company financial highlights on Slide four of the earnings presentation. First quarter revenue was $604 million, up 6% organically on a consolidated basis, with similar growth in both settings. Adjusted EBITDA was $115 million, up 4% year-over-year, as growth in commercial operations and lower corporate costs were partially offset by slightly lower government operations EBITDA. The lower corporate costs in the first quarter were mainly due to the timing of healthcare-related costs and are expected to return to a more normalized level over the next several quarters. We continue to see full-year unallocated corporate EBITDA at flat to slightly lower than 2023. Adjusted earnings per share was $0.76, up 9% compared to $0.70 in the prior year quarter. As you can see in the EPS bridge on Slide five, operations contributed about $0.02 to the year-over-year growth, with the remainder split between slightly higher pension and other income, lower interest expense, and a lower tax rate. For the full year, we expect the net impact of non-operational items to be relatively neutral to adjusted EPS compared to 2023, as various items around timing of certain expenses, FX gains, and interest expense that benefitted the first quarter will have offsets over the next three quarters. Our adjusted effective tax rate was 22.5% in the quarter, due to higher excess tax benefits and stock compensation expense. Nonetheless, we still expect a full-year tax rate of approximately 23.5%, meaning you could see a tax rate closer to that level over the next few quarters. Pre-cash flow in the quarter was $3 million, compared to a use of $43 million in the first quarter of 2023. Albeit modest, this was the first time we had positive free-cash flow in the first quarter since becoming a standalone company, highlighting our focus on working capital management and CapEx discipline. CapEx in the quarter was $30 million, and we continue to expect full-year CapEx to be flat to slightly down, compared to 2023, inclusive of early spend on the Cambridge facility that Rex discussed earlier. Moving now to the segment results on Slide 6. In government operations, first quarter revenue was up 6% to $487 million, driven by higher naval nuclear component production, special materials, and microreactor volume that was partially offset by lower long-lead material procurement. Despite higher revenue, first quarter adjusted EBITDA in the segment declined modestly to $100 million. This led to an EBITDA margin of 20%, 25%, compared to 22.5% in the first quarter of 2023, which benefited from a particularly strong mix and timing of certain items, both of which worked against us this quarter. For the full year of 2024, we continue to expect government operations EBITDA margins to be down, only slightly, from 21.1% in 2023, due to a few key dynamics. Those include grinding through onboarding inefficiencies and higher labor rates after growing our workforce by 10% last year, absorbing outsized revenue growth in cost plus microreactor projects and other new programs, and the absence of the missile tube expense recovery in the fourth quarter of 2023. Providing quarterly margin guidance can be challenging, but at this juncture, our best view is that government EBITDA margins in the second and third quarter will be similar to the 20%, 25% we reported in the first quarter, with a typical slight seasonal lift in the fourth quarter. Again, all of this leaves us right in line with the government operations margin guidance we gave last quarter. Turning to commercial operations, revenue was up 7%, driven by increases in field service activity in our commercial nuclear business, as well as robust BWXT medical revenue growth, and partially offset by lower nuclear components and fuel handling volume. Commercial operations adjusted EBITDA was up about $5 million to $14 million. The increase was driven mainly by improved performance in medical, which was partially offset by slightly lower contribution from commercial nuclear. This led to commercial EBITDA margin of 11.9%, up from 8.2% last year. We continue to expect commercial operations growth of high single digits to low double digits in 2024, with higher EBITDA margins compared to 2023. Growth will be led by medical, with commercial nuclear contributing as well, particularly in the second half of the year. Turning now to guidance on Slide seven. We are reaffirming our guidance for the four key metrics we provided last quarter. We project total company revenue and adjusted EBITDA growth in the mid-single digits, leading to revenue of at least $2.6 billion, and adjusted EBITDA of approximately $500 million. Included in this forecast is a year-over-year D&A step-up of approximately $10 million, driven mostly by government operations, as the new equipment and capacity we have invested in for our naval propulsion business and microreactor projects are more fully utilized. As such, we are reaffirming our adjusted EPS guidance of $3.05 to $3.20. As for the quarterly cadence of earnings, we expect slightly higher operating results on a sequential basis over the next two quarters and a seasonal pickup in the fourth quarter. On the sequential progression of non-operating items, we expect the next three quarters to have higher net interest expense, slightly lower other income, and a higher tax rate. In total, this should lead to EPS in the second and third quarters being relatively consistent with the first quarter, and then a seasonally stronger fourth quarter. Lastly, we are maintaining our free cash flow guidance of $225 million to $250 million, driven by EBITDA growth and improved working capital management. Capital expenditures are expected to be flat to slightly down, inclusive of early spending on the Cambridge plan expansion and other select growth investments across our businesses. As discussed at Investor Day, we are keenly focused on driving improved free cash flow for both working capital management and CapEx discipline as we work toward our medium-term target of 90% free cash flow conversion. To sum it up, we had a good first quarter and our tracking to achieve our full year guidance. Our focus remains on capturing growth opportunities in our core businesses, innovating to pursue new markets, and driving operational excellence and financial performance. With that, we look forward to taking your questions.
Operator: [Operator Instructions] Your first question comes from the line of Scott Deuschle from Deutsche Bank (ETR:DBKGn). Please go ahead.
Scott Deuschle: Robb, just to clarify, was the year-over-year margin pressure at government operations this quarter entirely from the onboarding inefficiencies and cost-plus mix, or is there anything else in there that's dragging down the margins?
Robb LeMasters: No. The year-over-year margin [indiscernible] margin that you're referring to, the kind of 200 basis points, those were some of the pressures that we saw, Scott. But really, if you really look back to last year, you'll realize that that was the highest margin that we saw all year. So, that's the first thing to note. That quarter really enjoyed positives in a couple fashions. One was it had, if you go back and look, it had a kind of one-time positive uplift from TSG performance fees that normally you see over kind of the next couple of quarters. We also saw a really good NOG volume, and I think that had to do with just sort of a release in general as we got through the workforce ramp-up. That first quarter, we really saw some positives that we talked about, if you go back and look at the script. That was about half, honestly, that high point. The second half was the step down of that kind of 100 of the 200 basis points really came from less so inefficiencies in the way of describing mix, Scott, but more around just what's going on with some of our new projects. So, as we ramp up the U Metal project and the initiatives within AT, our advanced technology groups, specifically Pele and DRACO, all those businesses are just new for us, right? So, they come in at a lower margin. So, again, about half of it came from that extraordinary performance that we saw last year that was just kind of a real high point, and the other half came from really the ramping of what you could call mix, the ramping of some of these new projects.
Scott Deuschle: Okay. That's helpful, Robb. Then, Rex, I think this multi-year pricing negotiation was supposed to have finished up last year, I want to say, so it seems to be taking quite a bit longer than normal. I'm just curious if you can shed any light on what's driving that delay and whether you've got a bridge contract to help you kind of get through until you get the actual multi-year done. Thank you.
Rex Geveden: Yes. Sure, Scott. Of course, we completed the fuel part of that contract earlier. That one's in the bag. But, yes, the rest of it, we've been operating under a bridge contract for a period of time while we work out the negotiation details. I would say that the uncertainty around the FY'24 appropriations, that combined with a defense supplemental created some uncertainty about what funding would be available. And so, I'd say now that those are water under the bridge, we're in a position to get this across the finish line now. But your assertion's correct, right? We've been executing the work scope under that pricing agreement for a long time now through bridge contracts.
Operator: Your next question comes from the line of Bob Labick of CJS Securities. Please go ahead.
Bob Labick: So, Rex, you mentioned the drug master file for lutetium. I was just wondering if you could give us a little more update on the process of seeking Canadian approval for the irradiation of ytterbium up there in your target delivery system and everything, and then the other steps that it's going to take to get all the way through the DMF for lutetium.
Rex Geveden: For lutetium, okay. Well, so for lutetium and those other active pharmaceutical ingredients, that's a pretty simple process. And what happens there is that the pharmaceutical companies that are planning to use that radioisotope will reference our product and their filing to the FDA. So, it's a simpler and cleaner process, and the timing for that is we'll be in business on lutetium sometime next year, and I believe the same thing for ytterbium.
Robb LeMasters: Yes. That's right. Maybe just to give a little added color there, we're through the process of making targets, as you know. You need to get through that, and then ultimately you'll place those in a source of irradiation. There's two sites that we're going to be looking to irradiate material first at the Missouri reactor. That's sort of the first stage, and then ultimately, as you mentioned, Bob, in our TDS at OPG, we built that, obviously, for tech, but that has capability around irradiating ytterbium. So, we will have to go through some work to get that credential with the regulators, but that's in process as it relates to OPG, and we don't see that as an impediment on there. And then ultimately, we're also standing up a processing line for that irradiated material, Bob, as you know, to make active pharmaceutical ingredients, so that's one more step, and so we're rolling out the construction there. So, kind of moving along nicely as the market matures. Frankly, we're seeing a lot of different customers for both irradiated material as well as for API.
Bob Labick: Okay, super, and then just sticking with isotopes, obviously, you have a lot going on this quarter. I didn't hear any update on the Moly-99. Any news from the FDA, or when should we expect next information?
Rex Geveden: Yes. Thanks, Bob. Let me give maybe sort of a broad perspective on that product line and its development. I think for products like this, you can think about sort of three big phases, the research and development phase, of course, which we exited a long time ago, the industrialization phase, which we are going through right now, and then, of course, commercialization phase. That's what everyone's been most interested in. And so we're at the very tail end of industrializing that product line, and by the way, it's overlapping with commercialization of that product. And so when you think about the industrialization phase, the systems that we've described to you, and you've seen them, you've put your eyes on them for the most part, but it's really exercising the target delivery system and then exercising our radio chemistry and radio pharmacy lines. There's other things, too, waste management systems and other such, but those are the big three, and by the way, let me pause for a second and remind you that, as Robb said in his previous answer, we pivoted from a [indiscernible] radiation campaign and went directly to the target delivery system, which did cost us some schedule, but it avoids having to do a second filing to get that product approved by the FDA, so I think we're going to look in the rearview mirror and see that as a good decision. So where we are is we have exercised our target delivery system. We've run targets through the reactor at Darlington in a high neutron flux environment and produced high activity targets. We have exercised all four of those target elevators. We had to, frankly, had to work out some kinks in that system, which we have done so. It's working very well now. We have run those high activity targets through Radio Chem and Radio Pharm, and I would say that we are doing the final tweaking on both of those systems to get the product exactly right. I would say that we are very well pleased with the product quality. It meets all the drug pharmacopeia, and then we're working through sort of the final items of our checklist with the FDA. In the meantime, we've been focusing on the commercialization phase. There is quite a bit of enthusiasm in the market for this product, so we've been doing some product testing by way of sending our generators to radiopharmacy networks and tagging cold kits with our product. We're working through, in pretty serious ways now, supply agreements with the radiopharmacy networks, and we're working on logistics details now, the shipping costs, and how we distribute the product in particular with which radiopharmacy. So, I'd say I'm super well pleased with all that progress, and we're pushing through to the finish line.
Operator: Your next question comes from the line of David Strauss of Barclays (LON:BARC). Please go ahead.
Josh Korn: It's actually Josh Korn on for David. I wanted to ask about the expansion of the Cambridge plant for the SMRs. If you could give us anything on when you might see some of that elevated demand start to come through, and what the additional capacity might allow you to produce. Thanks.
Rex Geveden: Yes. Sure, Josh. I'll start with that one. Robb may want to add. So the thing that kind of tripped us over on making a decision on that capacity expansion was the formal announcement on Pickering. That's a very big project. We'll be making the steam generators, of which there are 48 for those four reactors, 12 per reactor. 48 steam generators. We're very likely to manufacture the feeders for that, heat exchangers, and other kinds of components. So, it's a lot. And when you look at what we have in that plant right now, we're making all the steam generators, replacement steam generators for the Bruce site. We're making feeders for the Bruce site, making heat exchangers for the Bruce site. We're doing feeders for the Darlington refurbishments. And now we've got this activity on the small modular reactor, the reactor pressure vessel, and we expect to receive firm orders for that in the next few months, as we said on the call. So, when you blend all that up, basically, if you walk through that plant, it is full. I mean, it is full. And so, we really need the capacity now. And our expectation is that we'll see the follow-on orders for the other three reactor pressure vessels. And there's other content on that reactor. There's refueling systems and various other things for which we will compete. And so, and then after that, the fast followers would be organizations like TVA, which is preparing the Clinch River site for the same type of small modular reactor. We hear of other utilities that are interested in that. And then potential reactors that would go into Poland and other places that you've heard us talk about. So, the demand seems to be coming in kind of a wave, and we've built out a capacity to be ready for that.
Robb LeMasters: Yes. I might just add that we've done a lot of business case. We've been talking about this with you guys even in the past couple quarters, and we really wanted to do a business case to say, can we make the numbers work on the expansion with essentially the book of business that we have, right? And then leave the upside of being able to either serve international or U.S. demand on the SMR side, that sort of gravy to this. So, as Rex said, as you have the Darlington OPG refurb kind of come to an end at some point, then you're ramping up on the Bruce Power, and then ultimately the Pickering, all that refurb work, and then you have the GE Hitachi work of the first SMR and the likely follow-on. That really kind of makes you the business case, and then you want to have a tail of opportunity that ultimately pushes it to a really good business case, and that's when I looked at international growth, [Chernobyl] [ph], either refurbs, you're talking now more about greenfields, and so all of that can't be priced into counting on it, but really will seem to be quite clever if that all comes through. So, we're pretty excited about the economics of that build-out.
Operator: Your next question comes from the line of Peter Arment of Baird. Please go ahead.
Peter Arment: Nice results. Hey, maybe just to stay on that topic on Pickering, could you talk about, I think at your Investor Day you highlighted that some of these refurbishment projects that BWX kind of content was roughly about 10% of the total project costs. Is that, would that be similar for Pickering, and when would we expect actually the ordering of the longleaf materials to start?
Rex Geveden: So, on Pickering, let me see, Peter, I don't know if I could give a rule of thumb on percentage of total project cost, but you can think of the opportunity as being similar in scale to the -- I think a good comparison point would be the Bruce reactors where we built the steam generators for all those, and that was $600 million, $650 million Canadian contract, I believe, at the time. So, maybe factor in a little bit of escalation and a larger number of steam generators. Then you can add the feeders to that and heat exchangers. That's sort of a billion-dollar scale opportunity there, and I don't know the total project cost estimate from OPG, but it's, obviously, that's a sizable opportunity.
Peter Arment: Okay. That's helpful. And then just, when does the longleaf materials kind of activity begin? Obviously, you're putting the CapEx in place in front of that.
Robb LeMasters: Yes. I can take that one. Yes, so they're already talking about whether or not that longleaf material could come in the near term, and they're also looking at a schedule to get after a set of those in a more sequential basis to ultimately drive down the cost. So, I wouldn't be surprised if you get a more upfront order, but we're working through that with the customer and see how quickly they want to move, but I think in the near term.
Peter Arment: That's helpful. And then just regarding Romania, is there any updates there in terms of, you mentioned the export financing is in place, when would we think about kind of order timing on that one?
Robb LeMasters: Yes. I can take that too. It's still looking, it's kind of a year or two out to when it will sizably hit our books. That date's moving around, but they're moving forward. The OEM and EPC are moving forward, and so we're starting to see schedules put out and starting to get our business lined up. So, I would say it's sort of, call it two to three years out for it to be meaningful for us.
Peter Arment: Thank you, Robb. Just, lastly, on the CapEx part, Robb. So it sounds like you had already kind of planned for this, so CapEx doesn't seem like it goes up at all very much. Are we thinking about this kind of similar level next year, just given this announcement, or do you think this is kind of like a little bit of growth CapEx that you're putting in place?
Robb LeMasters: Yes. The way I'd describe it is to go back to Investor Day, right, we had a little bit over $100 million, $110 million, if you just look at 4% of sales. And then, we were finishing off the microreactor projects from last year. So, that probably put us at the lower end, if you will, of our sort of guidance, right, the free cash flow range that I have out there, includes a couple different scenarios. So, maybe on the upper end of free cash flow, you might say, you're going to have $125 million, $130 million of CapEx, and so for this year, that could tilt us from a CapEx standpoint to, as we've got out of Cambridge, to be sort of at the upper end, but we fully expect to offset that with all the goodness that we're seeing in operating cash flow. So that's what allows us to kind of remain in our range, is that even if we spend, $10 million to $20 million on this project this year, that was sort of contemplated, we could absorb that with all the good initiatives we have on operating cash flow. I think it's a tad too early to talk when you say next year.
Peter Arment: Thanks so much, Robb.
Robb LeMasters: Yes. No problem. Just a comment about next year. I think it's a little far out, but I don't see any major changes in this project, it can live within that normal budget.
Operator: Your next question comes from the line of Pete Skibitski of Alembic Global. Please go ahead.
Pete Skibitski: Just one for me, Rex. You touched earlier in the opening comments about the 24-baseline budget and supplementals approved, and I think there was $3.3 billion in the SIB funding. I guess, A, does any of that SIB money go to you guys at all, or basically you're just doing okay and you're already facilitated, so it goes to other suppliers? And then, any changes at all between the 24 budgets and the new 25 budgets at NASA or DOE with anything you guys are interested in there? Thanks.
Rex Geveden: Let's see here. On the submarine-based industrial funding, it is for the broad submarine industrial base, which could include us, Pete, and that would, of course, come through our customer. I'd say there's more to come on that as to what, if any, of that would get to us. And would you repeat the second question again for me?
Pete Skibitski: Yes. Just in the 25, fit-up that got released, with regard to NASA and DOE, I was just wondering if there's anything, kind of new or interesting nuclear-wise that you saw in those budgets, the plans there?
Rex Geveden: Oh, new and interesting nuclear-wise? Probably not, but I would say that, we're continuing to see sustained and very good support for the programs of record, like DRACO and Pele, and hopefully that will continue.
Operator: Your next question comes from the line of Michael Ciarmoli from Truist. Please go ahead.
Michael Ciarmoli: Nice results. Maybe, Rex, just back to the multi-year pricing. Is that, I mean, you mentioned kind of maybe a delay. I don't know if that's the right word, but just what was going on with the fiscal 24, 25 budget. Is both Ford (NYSE:F), CBN sort of schedule a factor in kind of what's happening with that new multi-year contract?
Rex Geveden: Yes. I think that when we're working through those agreements with our customer, Mike, it's everything, right? So it's what is the shipbuilding schedule, what is the budget available, how many spares do they want to order, what's going on with escalation. So that blends up to a pretty complex thing, particularly right now with labor and materials inflationary pressure. So it's sorting through that. And by the way, certainly not unusual for other defense contractors to be on, bridge contracts to negotiate through these things. So it's all of that. It's all the above. It was the FY 25, 24 appropriation. It was the supplemental, and it's the shipbuilding schedule and the President's budget request all blended up into what do we have here. And we'll certainly sort it out.
Michael Ciarmoli: Got it. Got it. And then, Robb, just on the, back to the medical and the TC99, any sort of change in your thought process? I mean, it's, I guess, directionally maybe it sounds like the TC99 approval is sliding to the right a little bit, but still comfortable with the trajectory of 24 and 25 revenues there for overall medical pushing to, $200 million and I guess getting that margin into the mid-30s?
Robb LeMasters: Yes. No, I don't think there is any change really, overall. Again, we don't anticipate any tech really moving the needle this year. In 2024, we talked about that last quarter. We're not really seeing. We're going to try to get commercial, but the actual impact will be minor in the near term. Ultimately, as we laid out that target, we said that it would really come from a couple different areas, our core portfolio, the therapeutics portfolio, and then the last area is the tech portfolio. And if you move through those and you really think about it, there's been some pretty good upside on the [Nordeon] [ph]. I think therapeutics is, at least from a market standpoint, surprising. We need to get some contracts. We talked about Lutetium. We're the only commercial supplier in Actinium, so I wouldn't be surprised if it gets surprised to the upside there. And then tech, for all the fits and starts that we've had is actually lining up pretty nicely. The market is ready for a third player, and so I wouldn't be surprised if we nail that one as well. So the target overall for call it 25, 26, year to have that level of 200 million revenue still seems readily achievable.
Michael Ciarmoli: Got it. And then just last one for me, just, Robb, given your background, what were your thoughts when you saw Fusion kind of pre-revenue, pre-EBITDA getting acquired for $2 billion, knowing what you guys have in terms of your medical business?
Robb LeMasters: Yes. I thought it was a solid acquisition, I think, for the acquirer. We're working very closely, as you know, with press release that we're working closely with a couple of key companies. One of them is Fusion, and we've been constantly impressed with their products and their knowledge that understanding how to get supply of the actinium, which is what their drugs are really based on, is key. And if you read the press release from the acquirer, they're really focused on the fact that they could bring that to bear to the parent company. So it's not only the products they have, but the knowledge of the supply chain, and we're a partner there. So in an indirect way, they're affirming our strategy that that's really a key aspect to what makes that company solid. I think I've always been transparent that we don't sell, we're not into drug business. So those evaluations really are multiples of revenue, if you will. And we're more of a picks and shovel player. But we're a very solid part of the ecosystem that I think really will warrant evaluation when we bring our whole business plan to bear. And I know everybody's been patient with that. But if we hit these targets, I think the valuation of that entity could be quite compelling.
Operator: Your next question comes from the line of Ron Epstein from Bank of America (NYSE:BAC). Please go ahead.
Ron Epstein: Just give me a quick one. When you look at the cadence for submarine production, it seems like, Virginia class has kind of been, I don't know, slowed down, given what the industry can do. And what impact does that have on you all? I mean, is it, are you kind of directly connected to that? Are you delivering, your stuff separately? I mean, how should we think about that?
Rex Geveden: Yes. Hey, Ron. I just touched on that in the script a little bit. I think you can think of us as somewhat decoupled from the shipyards. I mean, first off, the shipyards, HII and GD, are not our customers. We sell that product to naval reactors, and we sell it to them on their schedule. And then that's government furnished to the shipyards. So we're a little bit decoupled from that. And so I think that's a way to think about it. Another aspect here, maybe three things to think about. Another aspect to consider here is that, look, this is the president's budget request, and that's the shipbuilding schedule. But it doesn't mean that much until the authorizers and appropriators are done enacting the budgets for 25 and beyond. So I think it's certainly very early innings in that game of Virginia production. We've heard our, you know, our peer companies out there, HII and others, talking about how important it is to keep that production rate funding going. And obviously, very, very strong bilateral support for the Virginia program. So, you know, I'd say that one's not done yet. The third thing I would say is that the industrial base, ultimately, and BWXT, ultimately, have to get to a higher production rate in order to meet the needs for office. And so this Virginia rate needs to go to 2.3 for a decade or more. And so we've got to build the industrial capacity and the workforce capability to do that. And so slowing down doesn't make any sense to me. And so we'll see what the appropriators do. But it doesn't worry me all that much, given the depth of our backlog and given the strategic priority that the Virginia represents.
Ron Epstein: Got it. Got it. Yes, that makes sense. And then, I think you spoke to that some, but can you speak to, what's going on with labor for you all? I mean, labor has been a challenge for -- it seems like everybody across the space. I mean, is it been any different for you in retaining people, hiring people, and, you know, potentially the people that you're going to need to bring on board to eventually ramp up to meet the demand for the Navy?
Rex Geveden: Yes. I'd say maybe there's a couple of things I would say about that. And I talked about this a lot in prior calls, and that is that we reengineered our, you know, our talent acquisition process under Bob Duffy's leadership, who runs human capital for us over the last, let's call it a year and a half. And the fruits of that were we hired 10% of our total workforce last year, as we said in the script. And so we, there were two things there, right? We're able to achieve, largely achieve our growth needs, and do so in an environment where attrition post-COVID is higher than historically it has been. So I'd say that, you know, we sort of won on both sides of that one. All that said, it's a tough environment for labor, right? I think we're re-industrializing the U.S., the U.S. economy, and certainly trying to ramp up submarine production, and that's not an easy thing to do, and it's hard to get your hands on those scarce resources. And so, when Robb talked about the pressure that we're feeling on -- the pressure that we're getting in our margins, it has to do with onboarding that many people and that amount of churn. Our efficiencies are good. We're making this product, with the profit that we thought we would, but you've got a lot of people sitting in training classes, and you've got a lot of people, churning through overhead because of that. So I want to say that, that we've done a really good job of dealing with what I think is a very challenging environment, and we just have to keep swinging the axe at this thing. Robb, do you want to add anything?
Ron Epstein: Got it.
Robb LeMasters: No, I think you said it well. We're absorbing. We got ahead of the industry, I think, on CapEx to build the capacity, and we tried to do the same thing last year, really swarmed the issue of workforce, and so we got ahead of it, and others are also in our industry, but that's sort of how BWXT, goes about it. We try to just address the problem quickly. And now we're turning through it, as Rex said, our utilization at our top component sites are off almost 400 basis points year-over-year, but we're chewing through that, and we will all year. So we're sticking with our, our guidance, which shows that we can take all that workforce in and still keep moving. So I think we're going to be on the other side of this and be quite strong.
Operator: That concludes our Q&A session. I will now turn the conference back over to Chase Jacobson for closing remarks.
Chase Jacobson: Thanks, everybody, for joining us today. We will be speaking with many of you in the coming days and seeing many of you over the coming months. If you have any further questions, you can feel free to reach out at investors@bwxt.com. Thanks.
Operator: Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.